Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973441 | 1.00 | LMNA (0.69) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL5032675 | 0.82 | ALDH1A1 (0.53) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL5032618 | 0.82 | F2 (0.50) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL7141554 | 0.82 | MAPT (0.74) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL10016535 | 0.81 | SMN1; SMN2 (1.00) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL23345426 | 0.80 | KMT2A (0.77) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL7145890 | 0.80 | LMNA (0.77) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL12093538 | 0.80 | KMT2A (0.71) | LMNAKDM4EMEN1NPC1MAPT | |
| SCHEMBL687474 | 0.79 | LMNA (0.61) | LMNAKMT2ASMN1; SMN2CYP19A1POLB | |
| SCHEMBL11209446 | 0.79 | LMNA (0.65) | LMNAKDM4EMEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12435058-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4007753-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1964973-A | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | disclosed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | LMNA 3979/4885KDM4E 3638/4885MEN1 2675/4885 |
| US-12540129-B2 | KIF18A inhibitors | KIF18A, KIFC1, KIF2C | LMNA 1123/4885KDM4E 487/4885MEN1 3502/4885 |
| US-12435058-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | LMNA 2018/4885KDM4E 1372/4885MEN1 2120/4885 |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | LMNA 1184/4885KDM4E 3252/4885MEN1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.